scholarly journals Homologous and heterologous antibody responses to a one-year booster dose of an MF59®: Adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects

2012 ◽  
Vol 8 (7) ◽  
pp. 921-928 ◽  
Author(s):  
Timo Vesikari ◽  
Aino Forstén ◽  
Astrid Borkowski ◽  
Nikolaos Gaitatzis ◽  
Angelika Banzhoff ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Pandemic Influenza ◽  
Booster Dose ◽  
Antibody Responses ◽  
One Year ◽  
Heterologous Antibody

scholarly journals Assessment of Antigen-Specific and Cross-Reactive Antibody Responses to an MF59-Adjuvanted A/H5N1 Prepandemic Influenza Vaccine in Adult and Elderly Subjects

2012 ◽  
Vol 19 (12) ◽  
pp. 1943-1948 ◽  
Author(s):  
Iván Bihari ◽  
Gyula Pánczél ◽  
Jozsef Kovacs ◽  
Jenny Beygo ◽  
Elena Fragapane
Keyword(s):  
Influenza Vaccine ◽  
Vaccine Strain ◽  
Influenza Pandemic ◽  
Vaccine Dose ◽  
The Elderly ◽  
Antibody Responses ◽  
Elderly Subjects ◽  
H5n1 Influenza ◽  
Reactive Antibody ◽  
Heterologous Antibody

ABSTRACTPreparedness against an A/H5N1 influenza pandemic requires well-tolerated, effective vaccines which provide both vaccine strain-specific and heterologous, cross-clade protection. This study was conducted to assess the immunogenicity and safety profile of an MF59-adjuvanted, prepandemic influenza vaccine containing A/turkey/Turkey/01/2005 (H5N1) strain viral antigen. A total of 343 participants, 194 adults (18 to 60 years) and 149 elderly individuals (≥61 years), received two doses of the investigational vaccine given 3 weeks apart. Homologous and heterologous antibody responses were analyzed by hemagglutination inhibition (HI), single radial hemolysis (SRH), and microneutralization (MN) assays 3 weeks after administration of the first vaccine dose and 3 weeks and 6 months after the second dose. Immunogenicity was assessed according to European licensure criteria for pandemic influenza vaccines. After two vaccine doses, all three European licensure criteria were met for adult and elderly subjects against the homologous vaccine strain, A/turkey/Turkey/1/2005, when analyzed by HI and SRH assays. Cross-reactive antibody responses were observed by HI and SRH analyses against the heterologous H5N1 strains, A/Indonesia/5/2005 and A/Vietnam/1194/2004, in adult and elderly subjects. Solicited local and systemic reactions were mostly mild to moderate in severity and occurred less frequently in the elderly than in adult vaccinees. In both adult and elderly subjects, MF59-adjuvanted vaccine containing 7.5 μg of A/Turkey strain influenza virus antigen was highly immunogenic, well tolerated, and able to elicit cross-clade, heterologous antibody responses against A/Indonesia and A/Vietnam strains 6 weeks after the first vaccination.

AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice

Vaccine ◽  
2010 ◽  
Vol 28 (18) ◽  
pp. 3076-3079 ◽  
Author(s):  
Catherine Caillet ◽  
Fabienne Piras ◽  
Marie-Clotilde Bernard ◽  
Aymeric de Montfort ◽  
Florence Boudet ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Pandemic Influenza ◽  
Influenza A ◽  
Seasonal Influenza ◽  
Antibody Responses ◽  
Seasonal Influenza Vaccine ◽  
Influenza A H1n1

scholarly journals Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret Model

Vaccines ◽  
2021 ◽  
Vol 9 (1) ◽  
pp. 40
Author(s):  
Wen-Chun Liu ◽  
Raffael Nachbagauer ◽  
Daniel Stadlbauer ◽  
Shirin Strohmeier ◽  
Alicia Solórzano ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Influenza A ◽  
Influenza Virus Infection ◽  
Influenza Virus Vaccine ◽  
Antibody Responses ◽  
Upper Respiratory Tract ◽  
Influenza A Viruses ◽  
Humoral And Cellular Immunity ◽  
Stalk Domain ◽  
One Year

Epidemic or pandemic influenza can annually cause significant morbidity and mortality in humans. We developed novel chimeric hemagglutinin (cHA)-based universal influenza virus vaccines, which contain a conserved HA stalk domain from a 2009 pandemic H1N1 (pH1N1) strain combined with globular head domains from avian influenza A viruses. Our previous reports demonstrated that prime-boost sequential immunizations induced robust antibody responses directed toward the conserved HA stalk domain in ferrets. Herein, we further followed vaccinated animals for one year to compare the efficacy and durability of these vaccines in the preclinical ferret model of influenza. Although all cHA-based immunization regimens induced durable HA stalk-specific and heterosubtypic antibody responses in ferrets, sequential immunization with live-attenuated influenza virus vaccines (LAIV-LAIV) conferred the best protection against upper respiratory tract infection by a pH1N1 influenza A virus. The findings from this study suggest that our sequential immunization strategy for a cHA-based universal influenza virus vaccine provides durable protective humoral and cellular immunity against influenza virus infection.

Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans

Vaccine ◽  
2010 ◽  
Vol 29 (2) ◽  
pp. 166-173 ◽  
Author(s):  
Brian A. Crowe ◽  
Peter Brühl ◽  
Marijan Gerencer ◽  
Michael G. Schwendinger ◽  
Andreas Pilz ◽  
...  
Keyword(s):  
Immune Responses ◽  
Influenza Vaccine ◽  
Pandemic Influenza ◽  
Cellular Immune Responses ◽  
Cellular Immune
Sign in / Sign up

Export Citation Format

Share Document